Inoue T, Tanaka Y
Glob Health Med. 2025; 7(1):67-71.
PMID: 40026851
PMC: 11866904.
DOI: 10.35772/ghm.2024.01097.
Matthews P, Wang T, Barnes E
JHEP Rep. 2025; 7(2):101280.
PMID: 39867684
PMC: 11762194.
DOI: 10.1016/j.jhepr.2024.101280.
Wang J, Qiu K, Zhou S, Gan Y, Jiang K, Wang D
Ann Med. 2025; 57(1):2455539.
PMID: 39834076
PMC: 11753015.
DOI: 10.1080/07853890.2025.2455539.
Sun Y, Dong Y, Cui X, Guo X, Zhang J, Yu C
Mar Drugs. 2024; 22(7).
PMID: 39057397
PMC: 11278422.
DOI: 10.3390/md22070288.
Whyler N, Pyle A, Krishnaswamy S, Said J, Giles M
Womens Health (Lond). 2024; 20:17455057241265083.
PMID: 39051642
PMC: 11273580.
DOI: 10.1177/17455057241265083.
Serum HBV RNA levels among untreated adults with chronic hepatitis B in distinct immune phases and liver histopathology statuses.
Xu Q, Ding H, Bai T, Huang R, Wang J, Zhang J
J Mol Histol. 2023; 54(6):739-749.
PMID: 37843699
DOI: 10.1007/s10735-023-10162-5.
Hepatitis B core-related antigen: A novel and promising surrogate biomarker to guide anti-hepatitis B virus therapy.
Inoue T, Watanabe T, Tanaka Y
Clin Mol Hepatol. 2023; 29(4):851-868.
PMID: 36891607
PMC: 10577333.
DOI: 10.3350/cmh.2022.0434.
A nomogram based on HBeAg, AST, and age to predict non-minimal liver inflammation in CHB patients with ALT <80 U/L.
Zhang L, Bi X, Chen X, Zhang L, Xiong Q, Cao W
Front Immunol. 2023; 13:1119124.
PMID: 36741383
PMC: 9892180.
DOI: 10.3389/fimmu.2022.1119124.
Hepatitis B and Hepatitis D Viruses: A Comprehensive Update with an Immunological Focus.
Sausen D, Shechter O, Bietsch W, Shi Z, Miller S, Gallo E
Int J Mol Sci. 2022; 23(24).
PMID: 36555623
PMC: 9781095.
DOI: 10.3390/ijms232415973.
Drug Discovery Study Aimed at a Functional Cure for HBV.
Watanabe T, Hayashi S, Tanaka Y
Viruses. 2022; 14(7).
PMID: 35891374
PMC: 9321005.
DOI: 10.3390/v14071393.
Oxidative Stress in Chronic Hepatitis B-An Update.
Popa G, Popa M
Microorganisms. 2022; 10(7).
PMID: 35888983
PMC: 9318593.
DOI: 10.3390/microorganisms10071265.
Characteristics of HBV Novel Serum Markers across Distinct Phases in Treatment-Naïve Chronic HBV-Infected Patients.
Liao H, Li L, Zheng W, Zou J, Yu G, Si L
Dis Markers. 2022; 2022:4133283.
PMID: 35872701
PMC: 9303147.
DOI: 10.1155/2022/4133283.
Hepatitis B Core-Related Antigen and New Therapies for Hepatitis B.
Watanabe T, Inoue T, Tanaka Y
Microorganisms. 2021; 9(10).
PMID: 34683404
PMC: 8537336.
DOI: 10.3390/microorganisms9102083.
Farnesoid X receptor agonist for the treatment of chronic hepatitis B: A safety study.
Erken R, Andre P, Roy E, Kootstra N, Barzic N, Girma H
J Viral Hepat. 2021; 28(12):1690-1698.
PMID: 34467593
PMC: 9293351.
DOI: 10.1111/jvh.13608.
Soluble programmed death-1 is predictive of hepatitis B surface antigen loss in chronic hepatitis B patients after antiviral treatment.
Tan N, Luo H, Kang Q, Pan J, Cheng R, Xi H
World J Clin Cases. 2021; 9(21):5812-5821.
PMID: 34368300
PMC: 8316942.
DOI: 10.12998/wjcc.v9.i21.5812.
New Markers in Monitoring the Reactivation of Hepatitis B Virus Infection in Immunocompromised Hosts.
Svicher V, Salpini R, Malagnino V, Piermatteo L, Alkhatib M, Cerva C
Viruses. 2019; 11(9).
PMID: 31450680
PMC: 6784136.
DOI: 10.3390/v11090783.
The Role of Hepatitis B Core-Related Antigen.
Inoue T, Tanaka Y
Genes (Basel). 2019; 10(5).
PMID: 31075974
PMC: 6562807.
DOI: 10.3390/genes10050357.
Diagnostics of Hepatitis B Virus: Standard of Care and Investigational.
Jackson K, Locarnini S, Gish R
Clin Liver Dis (Hoboken). 2019; 12(1):5-11.
PMID: 30988902
PMC: 6385904.
DOI: 10.1002/cld.729.
Hepatitis: No cure for hepatitis B and D without targeting integrated viral DNA?.
Cornberg M, Manns M
Nat Rev Gastroenterol Hepatol. 2018; 15(4):195-196.
PMID: 29382951
DOI: 10.1038/nrgastro.2017.185.
Current advances in the elimination of hepatitis B in China by 2030.
Zhang S, Wang F, Zhang Z
Front Med. 2017; 11(4):490-501.
PMID: 29170919
DOI: 10.1007/s11684-017-0598-4.